Gow-Mac Receives Export Accolade
Gow-Mac Instrument Co, a provider of instruments and components for use in gas analysis and gas chromatography has been recognised by the US Department of Commerce for innovation and export of products to foreign companies. Jeffrey B. Lawson, President, and Kenneth B. Fincke, Vice President, were presented with an Export Achievement Certificate (EAC) at Gow-Mac’s company headquarters in Bethlehem, PA, at the end of last year. The award is given to companies that have increased exports, remained in good financial standing, and have benefited from the Department’s export assistance
with expansion of sales into new foreign markets. Over the last three years exports were said to be the driving force behind company growth, with its global representative and distributor network also growing to meet the demand for instrument sales and service. The company has continued to utilise Pennsylvania’s trade program and that of the US Department of Commerce to build on this momentum. “With assistance from these organisations, Gow-Mac has successfully developed new markets or increased sales to countries such as China, South Korea, India, Turkey, and Russia,” said Ken Fincke.
Gow-Mac celebrates Export Award from US Department of Commerce
TO FIND OUT MORE CIRCLE NO. 79 Bruker seals $1.3 Million Equipment Deal
An order from ThyssenKrupp Stainless USA in Calvert, Alabama to supply nearly $1.3 million in elemental analysis systems and automation equipment for its new stainless steel melt shop has been announced by Bruker.
“We are honoured to have been selected by ThyssenKrupp Stainless USA as supplier of laboratory instrumentation for their ambitious and exciting project,” stated Georg Schick, Bruker
Elemental Division Vice President for Industrial Sales & Marketing. “Providing integrated, multiple elemental analysis technologies from a single supplier makes things easier for clients looking for complete solutions.”
The contract includes an industrial analysis automation system with automatic milling, X-ray fluorescence (XRF) and spark optical emission spectrometry (OES) systems for the analysis of
stainless steel, as well as individual laboratory instruments, such as combustion gas analysers for oxygen, nitrogen, carbon and sulphur, and XRF for slag determination.
“We searched for the most economic and reliable solution, to get fast and precise analysis results,” said ThyssenKrupp Stainless USA’s Director of Quality Dr Joerg-Friedrich Holzhauser. “With Bruker we found an excellent partner to fulfil all our targets.”
TO FIND OUT MORE CIRCLE NO. 80
Varian Books $77 Million Order to Riyadh Medical Centre
Varian Medical Systems has booked a $77 million order with Saudi Particle Therapy Centre LLC to equip a new proton therapy facility at the King Fahd Medical Center in Riyadh, Saudi Arabia. Varian will equip the new centre with a ProBeam™ system for five treatment rooms as well as two TrueBeam™ medical linear accelerators. Equipment delivery and installation is expected to commence in spring 2013 and patient treatments are scheduled to begin in late 2014. The agreement will also include a multi-year service contract that should commence as the installation is completed.
"We are honoured to have been selected to supply
our equipment and software for this prestigious new facility, which will make life-saving proton therapy treatments available for the first time to cancer patients in this region," said Tim Guertin, Varian's Chief Executive Officer. "This is an exciting step forward for our Varian Particle Therapy business."
Proton therapy makes it possible to treat certain types of cancer more precisely and with potentially fewer side effects than with conventional radiation therapy. With proton therapy, the risk of damage to healthy tissues is reduced. The method can be applied for many of the most common types of
cancer and offers advantages when treating tumours close to radiosensitive tissues. In pediatric patients the risk of developing a new, radiation-induced cancer later in life can be reduced.
"We believe that more and more proton centres will want to employ the full suite of Varian products and technology for radiotherapy and radiosurgery as well as particle therapy for world-class cancer treatments," said Guertin. "The combination of these technologies based on 60 years of innovation puts Varian in a unique position to help advance clinical care for patients around the world.
TO FIND OUT MORE CIRCLE NO. 82
GR Scientific Partners with US Instrument Manufacturer
GR Scientific (GRS), a UK manufacturer of electrochemical and titration instruments, has signed a partnership with Ayalytical Instruments, a provider of instrumentation to the petroleum, biofuels, lubricants and materials testing industries.
The partnership, which started at the beginning of January, covers distribution of GRS products, accessories and consumables throughout the United States and Latin America. Managing Director of Ayalytical Instruments, Juan Ayala, will serve as liaison between the two companies to ensure a seamless transition.
“GR Scientific’s product range is expanding quickly, and our partnership addresses critical needs of our end users – greater technical and marketing support,” said Mr Ayala. “We look forward to a long-term successful partnership.”
George Robertson, General Manager, GRS ( left) and Juan Ayala, Managing Director of Ayalytical Instruments.
TO FIND OUT MORE CIRCLE NO. 83
European Centre Enhances LIMS Support
Labvantage has announced the recent opening of a new training centre at its Monza headquarters, located near to Milan, which offers training conducted in both Italian and English.
“Inaugurating a strategic business development centre here in Monza is critical to the LIMS market, availing business value to Labvantage and our customers, both in Europe and worldwide,” reaffirmed Paolo Concio, Director of European Sales for the company. “We now take that success to the next level with a fully equipped European headquarters, expanding upon our existing Kolkata and Somerset branches.”
TO FIND OUT MORE CIRCLE NO. 81
Phenomenex Provides Direct Service for Sweden
Phenomenex Inc has expanded its international team to serve Sweden directly from its Scandinavian subsidiary. With products formally available through a distribution partner, the Phenomenex ApS office in Denmark now offers the research community in Sweden direct purchasing, rapid product delivery, helpful technical support and educational training seminars.
The Company’s European subsidiary network directly supports chromatographers in Germany, the United Kingdom, France, Italy, Austria, Ireland, Iceland, The Netherlands, Belgium, Luxembourg, Malta, Norway, Finland, Denmark and now Sweden.
"Phenomenex ApS will provide our growing customer base in Sweden with efficient purchasing including an award-winning e- commerce portal and product delivery along with local technical support and customer service," commented Fasha Mahjoor, CEO and President of Phenomenex. "We are proud to continue the expansion of our international operations to better serve customers worldwide."
TO FIND OUT MORE CIRCLE NO. 84 PolyTherics Acquisition Advances Scope for Biopharmaceuticals
PolyTherics Ltd a provider of solutions for the improvement of protein and peptide based drugs has acquired Warwick Effect Polymers (WEP) which provides specialty biopolymers for the modification of biological products. WEP has developed two proprietary biopolymer technologies, PolyPEG®
and GlycoPol® or GlycoPol® , both of which are based
on the leading academic work of Professor David Haddleton of the University of Warwick utilising Living Radical Polymerisation. WEP has agreements with several global pharmaceutical and biotechnology companies for the evaluation of PolyPEG®
technologies this year. PolyPEG® biopharmaceuticals and which is especially applicable to high concentration protein products. GlycoPol®
and the company expects to announce licensing deals for these is a novel low viscosity comb polymer for extending the duration of action of is a
novel glycopolymer for targeting the delivery of therapeutic agents, including RNAi and aptamer molecules, to specific glycan receptors on cells and has the potential to facilitate their intracellular uptake.
PolyTherics’ proprietary conjugation technologies, TheraPEG™, CyPEG™ and HiPEG™, have been used extensively to attach polymers, mainly poly(ethylene) glycol (PEG), to specific sites on proteins and peptides to extend their duration of action and, more recently, to produce antibody drug conjugates for delivery of imaging agents or cytotoxic drugs to target cells. “With this acquisition of WEP, PolyTherics now has broader technology capabilities for the pharmaceutical and biotechnology company partners that the two companies have separately served,” commented John Burt, CEO of PolyTherics. “This acquisition enables the combined businesses to provide a portfolio of best-in-class technologies to enable better biopharmaceuticals which will benefit patients.” Dave Haddleton commented: “The combination of PolyTherics’ technologies with our specialty polymers technology is an exciting prospect for future partnerships and will allow the most effective package for our partners.”
TO FIND OUT MORE CIRCLE NO. 85
Read all the latest News & Views, Articles and New Product Releases Online, visit:
www.labmate-online.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92
